Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neo

Trial Details

NCT ID
NCT07016724
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • cadonilizumab combined with neoadjuvant radiochemotherapy
  • neoadjuvant radiochemotherapy
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • diagnosed with esophageal squamous cell cancer;
  • staged with cT1N+M0/cT2-3N0-3M0;
  • experienced no cancer-related treatment;
  • Expected survival more than 6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →